Overview of Dr. Abdel-Wahab
Dr. Omar Abdel-Wahab is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Duke University School of Medicine and has been in practice 13 years. Dr. Abdel-Wahab accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
- Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
- Duke University School of MedicineClass of 2004
Certifications & Licensure
- NY State Medical License 2007 - 2026
- NJ State Medical License 2022 - 2025
- MA State Medical License 2006 - 2009
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia.Qi Jin, Ethan Harris, Jacquelyn A Myers, Rashid Mehmood, Anitria Cotton
Blood. 2024-12-05 - Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.Leora Boussi, Jeetayu Biswas, Omar Abdel-Wahab, Eytan Stein
British Journal of Haematology. 2024-12-01 - Covalent targeting of splicing in T cells.Kevin A Scott, Hiroyuki Kojima, Nathalie Ropek, Charles D Warren, Tiffany L Zhang
Cell Chemical Biology. 2024-11-22
Abstracts/Posters
- Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid LeukemiasOmar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant LeukemiasOmar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with HclOmar Abdel-Wahab, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- RUNX1 Deficiency Cooperates with SRSF2 Mutation to Further Disrupt RNA Splicing and Exacerbate Myelodysplastic Syndromes in Mouse Models2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- FDA Approves First Treatment for Patients with All Forms of HistiocytosisJanuary 30th, 2023
- Nurix Therapeutics Presents Positive Clinical Results from Its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual MeetingDecember 12th, 2022
- Clinical Pathology Selected AbstractsJune 23rd, 2022
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
First Health PPO
GHI PPOGreat West PPO
Health Net Oregon PPO
HealthAmerica HealthAssurance PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
Regence Washington - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: